Friday, September 6, 2013
Morphotek has formed two agreements with Fox Chase Cancer Center to acquire clinical samples essential for the development and validation of companion diagnostic assays. The assays will be used in the identification of patients who will be suitable for treatment with targeted antibody therapeutics currently being developed by Morphotek.
Oncobiologics and Fox Chase Cancer Center have agreed to co-develop a novel, next-generation bi-specific antibody cancer platform with enhanced therapeutic capabilities against solid tumors. The jointly engineered platform is designed to handle multiple targets, representing a pipeline of promising cancer treatments. This research program is now underway, with preclinical studies expected in Q1-2012 for the first molecule using this platform.